Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcgamma receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.
Purity:
>97.0%
CAS Number:
[1858168-59-8]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
